Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020

SELL
$4.1 - $10.24 $368,015 - $919,142
-89,760 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$3.16 - $6.73 $18,865 - $40,178
5,970 Added 7.12%
89,760 $570,000
Q3 2019

Nov 14, 2019

SELL
$3.55 - $5.4 $54,006 - $82,150
-15,213 Reduced 15.37%
83,790 $329,000
Q2 2019

Aug 14, 2019

BUY
$4.1 - $8.05 $187,361 - $367,868
45,698 Added 85.73%
99,003 $480,000
Q1 2019

May 15, 2019

SELL
$5.41 - $8.73 $35,110 - $56,657
-6,490 Reduced 10.85%
53,305 $437,000
Q4 2018

Feb 14, 2019

BUY
$5.39 - $9.15 $322,295 - $547,124
59,795 New
59,795 $331,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $395M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Brandywine Global Investment Management, LLC Portfolio

Follow Brandywine Global Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brandywine Global Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brandywine Global Investment Management, LLC with notifications on news.